Prosecution Insights
Last updated: November 04, 2026
Application No. 17/871,164

PROCESS FOR PREPARATION OF BIOLOGICALLY ACTIVE COPOLYMER

Final Rejection §103
Filed
Jul 22, 2022
Priority
Jan 31, 2020 — AU 2020900270 +1 more
Examiner
HUHN, RICHARD A
Art Unit
1764
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Recce Pharmaceuticals Ltd.
OA Round
4 (Final)
67%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
613 granted / 912 resolved
+2.2% vs TC avg
Moderate +6% lift
Without
With
+5.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
42 currently pending
Career history
945
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
41.4%
+1.4% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
26.1%
-13.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 912 resolved cases

Office Action

§103
DETAILED ACTION Any rejections and/or objections made in the previous Office action and not repeated below are hereby withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action. The grounds of rejection set forth below for claims 1-7, 12-13, and 20-23, and 25 are the same as those set forth in the previous Office action mailed on Apr. 16, 2026. For this reason, the present action is properly made final. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections – 35 U.S.C. § 103 Claims 1-7, 12-13, and 20-23, and 25 are rejected under 35 U.S.C. § 103 as being unpatentable over US 2017/0281669 A1 (herein “Melrose”) in view of Chemical Engineering and Processing, 2008, 47(12), 2029-2050 (herein “Anxionnaz”), US Patent No. 3,257,363 (herein “Miller”) and WO 00/00875 A1 (herein “Anderson”). As to claims 1 and 5-6: Melrose describes biologically active polymers (see the abstract). Melrose describes a process of making such a polymer (see Example 1 in ¶¶ [0124]-[0131]) comprising reacting polyethylene glycol (MW 200) with acrolein in an aqueous solution, and the temperature of the reactants was maintained between approximately 25 °C and 35 °C (see ¶ [0124]). The resulting polymer has a molecular weight of approximately 500 Daltons (see ¶ [0127]). Melrose more generally discloses that the process described therein may include maintaining the reaction temperature in the range of from 10 °C to 40 °C (see ¶ [0077]), and this range of temperatures overlaps the presently recited range of no more than 10 °C. Melrose does not specifically disclose an embodiment of a process performed at a temperature of 10 °C; Melrose does not disclose the use of a heat exchanger; and Melrose does not disclose computer control of the presently recited reaction parameters. Anxionnaz discloses various aspects of heat exchangers (see the abstract). Anxionnaz discloses that removing heat generated by an exothermic reaction is necessary to control the reaction temperature and to avoid thermal runaway reactions or to suppress endothermic by-product reactions (see section 2.1 on p. 2030). Anxionnaz discloses various heat exchangers including a stirred batch reactor with a double jacket through which a cooling fluid is passed (see the right of Fig. 1 on p. 2031). In light of the disclosure in Melrose that the reaction temperature is maintained in the range of from 10 °C to 40 °C, one of ordinary skill in the art would have been motivated to perform Melrose’s process at any temperature within the disclosed range, including at the temperature of 10 °C which fall within the scope of the presently recited range of no more than 10 °C. In light of the disclosure in Melrose that the reaction temperature is maintained within the disclosed range, one of ordinary skill in the art would have been motivated to use well-known techniques and equipment to maintain the reaction temperature. In light of Anxionnaz, it is evident that one of ordinary skill in the art would have been apprised of the use of heat exchangers such as a double jacket heat exchanger to control reaction temperature. One of ordinary skill in the art would further have been motivated by ordinary creativity to control the adjustable parameters of the double jacket heat exchanger (stirring rate, coolant flow rate, and coolant temperature) in order to achieve the desired amount of heat exchange. Miller describes polymerization reactor (see Fig. 1). Miller discloses a coolant jacket (see item 12) including the heat exchange medium water (see col. 2, l. 41). Anderson describes a system for controlling temperature of a polymerization process (see the abstract). Anderson discloses that PID or PI controllers (see p. 6, ll. 4-7) are used to achieve more effective control of the reactor temperature by controlling the temperature of coolant feeding a heat exchanger (see p. 6, ll. 26-29). In light of Anxionnaz’ disclosure of a cooling fluid, one of ordinary skill in the art would have been motivated by ordinary creativity to use any well-known cooling fluid in the jacket. In light of Miler, it is evident that one of ordinary skill in the art would have been apprised of the use of water as a heat exchange medium in a polymerization reactor. One of ordinary skill in the art would therefore have been motivated to perform the process of Melrose using a stirred batch reactor with a double jacket as described in Anxionnaz, as set forth above, while using water as the cooling fluid in the jacket. In light of Anderson, one of ordinary skill in the art would have been motivated to control the temperature of the water in the jacket to achieve more effective control of the reactor temperature. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have made the polymer of Melrose’s Example 1 using a stirred batch reactor with a double jacket, as described in Anxionnaz; to have used water as the cooling fluid in the jacket, as described in Miller; and to have used PID or PI controllers, as described in Anderson, to control the temperature of the water in the jacket to maintain the reaction at a temperature of 10 °C. As to claim 2: The cited process of Melrose’s Example 1 includes an aqueous solution at pH 12 (see ¶ [0124]). As to claim 3: The cited process of Melrose’s Example 1 includes an aqueous solution comprising about 38 wt% of water (see the amounts in ¶ [0124]). As to claims 4, 7, 12-13, 20-23, and 25: The cited process of Melrose’s Example 1 includes adding aqueous acrolein (about 20 wt% concentration) to aqueous polyethylene glycol (pH 12, about 25 wt% water) in a weight ratio of polyethylene glycol to acrolein of 12:1 (see the amounts in ¶ [0124]); and then adjusting the pH to 7.5 with acid (see ¶ [0125]). Allowable Subject Matter Claims 8 and 24 are objected to as being dependent upon a rejected base claim, but they would be allowable if written in independent form. Response to Arguments Applicant’s arguments filed Mar. 25, 2026 (herein “Remarks”) and the accompanying Declaration have been fully considered but they are not persuasive. Applicant argues generally (e.g. bottom of p. 9 of Remarks) that copolymers prepared at 25-35 °C (corresponding to the example of Melrose cited in the rejection) are significantly less active. The Declaration similarly states (item 16) that "co-polymers prepared at 25 °C to 35 °C are statistically significantly less active.” Allegations of unexpected results must be supported by evidence that establishes that the differences in results are in fact unexpected and unobvious and of both statistical and practical significance. MPEP 716.02(b). Applicant has not presented evidence drawn to a material prepared according to the example of Melrose at a temperature of “25 °C to 35 °C”. Because evidence drawn to Melrose’s material has not been presented, Applicant’s assertion in the Declaration does not identify evidence with which the argued statistical significance of a difference over Melrose could be established. Melrose (Table 1, p. 10) shows a kill concentration for the polymer of its Example 1, namely a concentration of 10 ppm against each of S. aureus and E. coli. The present application (Tables 2 and 15) shows a minimum inhibitory concentration of two of the inventive polymers: polymer E1 at a concentration of 30 ppm for both of S. aureus and E. coli (Table 2) but also at a concentration of 20 ppm for S. aureus and of 30 ppm for E. coli (Table 15); and polymer E2 at a concentration of 20 ppm for both of S. aureus and E. coli (Table 15). Because the present disclosure includes two examples of the polymer E1 that exhibits different minimum inhibitory concentrations against S. aureus (30 ppm in Table 2, and 20 ppm in Table 15), Applicant has not shown that the concentrations of 20 ppm and 30 ppm are statistically significantly different. The amount of uncertainty attached to the reported concentration values is presently unclear, and this weighs against a conclusion that the present showing establishes a statistically significant difference over Melrose. Allegations of unexpected results must be supported by evidence that is comparative to the closest prior art. MPEP 716.02(e). The concentrations reported by Melrose for killing the bacteria (see paragraph 25 above) are lower than the concentrations reported in the present application of the inventive polymers for inhibiting the bacteria. Additionally, the presently disclosed comparative examples that are prepared at higher temperatures (e.g. CE2, prepared at 30 °C) have much higher minimum inhibitory concentrations, suggesting their bactericidal concentrations would be still higher. For both of the two above reasons, the presently disclosed examples are not representative of the polymer of Melrose’s Example 1. Because the evidence of record does not properly compare to Melrose, it does not support a conclusion of an unexpected difference over Melrose. Applicant's disclosure does not include the same test of the present invention in the minimum kill concentration procedure that is described in Melrose. There is presently no evidence of record using a material prepared according to Example 1 of Melrose (at a temperature of 25 °C to 35 °C) in comparison to the inventive polymers. While the minimum bactericidal concentration and minimum inhibitory concentration are different tests, the best available evidence of record establishes that Melrose describes a material that is effective against each of S. aureus and E. coli at a concentration of 10 ppm. Because Applicant's results are not comparative to Melrose, and further because Applicant's results are drawn to a test that shows effectiveness at the higher concentrations of 20 or 30 ppm, no significant or unexpectedly improved difference in the performance over Melrose's material has been demonstrated. Applicant further presents remarks (items 22-29 of the Declaration) regarding the difficulty in comparing results of different tests. These remarks reinforce the necessity of making a comparison involving the same test using both the inventive material and the material made according to Melrose. Applicant further presents remarks (items 30-38 of the Declaration) regarding ultraviolet absorption measurements. The discussed differences in ultraviolet absorption measurements among polymers prepared at different temperatures imply some structural difference(s) in the polymers. The extent to which the polymers prepared at different temperatures may potentially have differences of practical significance appears to be drawn to the effectiveness against certain bacteria, such as for inhibition or killing. For the reasons given above, a proper comparison among the inventive material and the material made according to Melrose has not been made, and thus no significant or unexpectedly improved difference in the performance over Melrose's material has been demonstrated. Conclusion This action is properly final because the claims are rejected on the same grounds as set forth in the previous Office Action mailed on Apr. 16, 2026. Accordingly, THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). See MPEP § 706.07(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR § 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. This action is a final rejection and is intended to close the prosecution of this application. Applicant's reply under 37 CFR § 1.113 to this action is limited either to an appeal to the Patent Trial and Appeal Board or to an amendment complying with the requirements set forth below. If applicant should desire to appeal any rejection made by the examiner, a Notice of Appeal must be filed within the period for reply identifying the rejected claim or claims appealed. The Notice of Appeal must be accompanied by the required appeal fee. If applicant should desire to file an amendment, entry of a proposed amendment after final rejection cannot be made as a matter of right unless it merely cancels claims or complies with a formal requirement made earlier. Amendments touching the merits of the application which otherwise might not be proper may be admitted upon a showing of good and sufficient reasons why they are necessary and why they were not presented earlier. A reply under 37 CFR § 1.113 to a final rejection must include the appeal from, or cancellation of, each rejected claim. The filing of an amendment after final rejection, whether or not it is entered, does not stop the running of the statutory period for reply to the final rejection unless the examiner holds the claims to be in condition for allowance. Accordingly, if a Notice of Appeal has not been filed properly within the period for reply, or any extension of this period obtained under either 37 CFR 1.136(a) or (b), the application will become abandoned. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RICHARD A. HUHN whose telephone number is (571)270-7345. The examiner can normally be reached Monday through Friday, 9 AM to 6 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Arrie (Lanee) Reuther can be reached at (571) 270-7026. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD A. HUHN/Primary Examiner, Art Unit 1764
Read full office action

Prosecution Timeline

Show 4 earlier events
Mar 25, 2026
Request for Continued Examination
Mar 27, 2026
Response after Non-Final Action
Apr 16, 2026
Non-Final Rejection mailed — §103
Jul 30, 2026
Interview Requested
Aug 11, 2026
Examiner Interview Summary
Aug 12, 2026
Response Filed
Aug 12, 2026
Response after Non-Final Action
Oct 06, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781104
Hydrocarbon Polymer Modifiers Having High Aromaticity and Low Molecular Weight and Uses Thereof
3y 3m to grant Granted Nov 03, 2026
Patent 12780967
LOW DIELECTRIC RESIN COMPOSITION AND AN ARTICLE OF MANUFACTURE PREPARED THEREFROM
3y 1m to grant Granted Nov 03, 2026
Patent 12767753
SEQUENCE-BLOCK COPOLYMERS AND PREPARATION THEREFOR AND APPLICATION THEREOF
4y 5m to grant Granted Oct 20, 2026
Patent 12767796
MULTIMODAL POLYETHYLENE
2y 10m to grant Granted Oct 20, 2026
Patent 12760144
METHOD OF SPONTANEOUSLY PATTERNING A POLYMER DURING FRONTAL POLYMERIZATION
3y 4m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
67%
Grant Probability
73%
With Interview (+5.5%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 912 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month